Off-Label Use of Atypical Antipsychotics: An Update
Summary of Benefits: Post-traumatic Stress Disorder
Adjunctive treatment with risperidone reduces the symptoms of combat-related post-traumatic stress disorder (PTSD). The strength of evidence supporting this finding is moderate. As a treatment for abused women with PTSD, the evidence of benefits from risperidone is insufficient to determine an effect. The evidence for olanzapine and quetiapine is insufficient for analysis.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | post-traumatic stress | PTSD | risperidone | olanzapine | quetiapine
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.